Product Name: Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS NO:161798-03-4
Chemical & Physical Properties:
Appearance : white powder
Boiling Point:495.9℃ at 760 mmHg
Febuxostat is a new generation of xanthine oxidase inhibitors developed by emperor company of Japan. It is used to treat hyperuricemia (gout) clinically. Its structure is completely different from that of xanthine oxidase inhibitor developed 40 years ago. It is a new and highly effective non purine xanthine oxidase selective inhibitor. Xanthine oxidase is a key enzyme to promote uric acid production.
In February 2009, the U.S. Food and Drug Administration (FDA) approved febuxostat for long-term treatment of gout hyperuricemia patients.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.